Amid its plummeting stock value, layoffs and cuts to its drug R&D program, the battered company is carrying on.
23andMe CEO Anne Wojcicki knows the genetic-testing and ancestry-tracing company has been in "the eye of the storm" recently, but she said she's confident that the company is still viable and ...
It was a simple process. You’d collect a saliva sample, ship it off, and within six weeks, you’d receive a complete ancestral ...
In an exclusive interview with "CBS Mornings" co-host Gayle King, 23andMe CEO Anne Wojcicki discusses the challenges of ...
Hosted on MSN14d
Inside 23andMe CEO Anne Wojcicki's vision for the company: It "will transform health care"In an exclusive interview with "CBS Mornings" co-host Gayle King, 23andMe CEO Anne Wojcicki discusses the challenges of losing family, recent company changes, and her vision for the company's future.
NEW YORK (AP) — 23andMe is laying off 40% of its workforce, or more than 200 employees, and discontinuing its therapeutics division as the struggling genetic testing company attempts to slash costs.
DNA-testing company 23andMe said on Monday that it was firing roughly 40% of its workforce, more than 200 people, as Chief Executive Anne Wojcicki seeks to stabilize her money-losing business. As part ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback